CN103814015A - 用于治疗糖皮质激素受体介导的障碍的吲唑基酰胺衍生物的结晶形式 - Google Patents

用于治疗糖皮质激素受体介导的障碍的吲唑基酰胺衍生物的结晶形式 Download PDF

Info

Publication number
CN103814015A
CN103814015A CN201280039142.8A CN201280039142A CN103814015A CN 103814015 A CN103814015 A CN 103814015A CN 201280039142 A CN201280039142 A CN 201280039142A CN 103814015 A CN103814015 A CN 103814015A
Authority
CN
China
Prior art keywords
compound
treatment
another aspect
mammal
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280039142.8A
Other languages
English (en)
Chinese (zh)
Inventor
H.I.安德森
K.Y.康韦
M.J.奎伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
AstraZeneca AB
Original Assignee
Bayer Pharma AG
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, AstraZeneca AB filed Critical Bayer Pharma AG
Publication of CN103814015A publication Critical patent/CN103814015A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280039142.8A 2011-06-29 2012-06-27 用于治疗糖皮质激素受体介导的障碍的吲唑基酰胺衍生物的结晶形式 Pending CN103814015A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29
US61/502,656 2011-06-29
PCT/GB2012/051503 WO2013001294A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Publications (1)

Publication Number Publication Date
CN103814015A true CN103814015A (zh) 2014-05-21

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280039142.8A Pending CN103814015A (zh) 2011-06-29 2012-06-27 用于治疗糖皮质激素受体介导的障碍的吲唑基酰胺衍生物的结晶形式

Country Status (16)

Country Link
EP (1) EP2726464A1 (https=)
JP (1) JP2014527955A (https=)
KR (1) KR20140036230A (https=)
CN (1) CN103814015A (https=)
AR (1) AR086818A1 (https=)
AU (1) AU2012277514A1 (https=)
BR (1) BR112013031759A2 (https=)
CA (1) CA2839398A1 (https=)
IN (1) IN2014MN00023A (https=)
MX (1) MX2013014566A (https=)
RU (1) RU2013153466A (https=)
SG (1) SG195309A1 (https=)
TW (1) TW201305115A (https=)
UY (1) UY34170A (https=)
WO (1) WO2013001294A1 (https=)
ZA (1) ZA201309480B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108314670A (zh) * 2018-02-06 2018-07-24 江苏八巨药业有限公司 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法
CN116283781A (zh) * 2022-12-16 2023-06-23 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代n-苯基吲唑酰胺类化合物、药物组合物和用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN116528696A (zh) * 2020-11-27 2023-08-01 未来实验室生物科学有限公司 高纯度β烟酰胺单核苷酸（NMN）及其制造方法
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
MX2013000518A (es) 2010-07-21 2013-02-27 Aztrazeneca Ab Inhalador.
NZ605179A (en) 2010-07-21 2014-08-29 Astrazeneca Ab Inhaler

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108314670A (zh) * 2018-02-06 2018-07-24 江苏八巨药业有限公司 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法
CN116283781A (zh) * 2022-12-16 2023-06-23 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代n-苯基吲唑酰胺类化合物、药物组合物和用途
CN116283781B (zh) * 2022-12-16 2025-05-13 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代n-苯基吲唑酰胺类化合物、药物组合物和用途

Also Published As

Publication number Publication date
AR086818A1 (es) 2014-01-22
MX2013014566A (es) 2014-09-25
CA2839398A1 (en) 2013-01-03
ZA201309480B (en) 2015-10-28
UY34170A (es) 2013-01-31
JP2014527955A (ja) 2014-10-23
KR20140036230A (ko) 2014-03-25
IN2014MN00023A (https=) 2015-06-12
WO2013001294A1 (en) 2013-01-03
SG195309A1 (en) 2013-12-30
BR112013031759A2 (pt) 2016-12-13
RU2013153466A (ru) 2015-08-10
EP2726464A1 (en) 2014-05-07
TW201305115A (zh) 2013-02-01
AU2012277514A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
EP3743406B9 (en) Tmem16a modulators
CN102596917B (zh) 2-(4-((2-氨基-4-甲基-6-(戊基氨基)嘧啶-5-基)甲基)苯基)乙酸4-(二甲基氨基)丁酯的二糖精盐、二富马酸盐、二-(1-羟基-萘-2-甲酸)盐和单苯甲酸盐
CN104822678B (zh) 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
JP4723514B2 (ja) Ｃｂ１受容体親和性を有するｎ’−（１，５−ジフェニル−１ｈ−ピラゾール−３−イル）スルホンアミドの誘導体
KR20050047552A (ko) 베타-2 작용제로서의 인돌 유도체
TWI391391B (zh) 多晶型
EP2620435A1 (en) Phenyl and benzodioxinyl substituted indazole derivatives
CN103814015A (zh) 用于治疗糖皮质激素受体介导的障碍的吲唑基酰胺衍生物的结晶形式
CA3170664A1 (en) P2x3 modulators
JP2016525508A (ja) 嚢胞性線維症の処置のための化合物
CN102947299B (zh) 生物碱氨基酯衍生物及其药物组合物
EP3650444B1 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
CA3145120A1 (en) Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
WO2019015640A1 (zh) 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途
CN109096218B (zh) 盐酸奥达特罗晶型a及其制备方法
CN108997248B (zh) 盐酸奥达特罗晶型b及其制备方法
HK40100130A (zh) 制备普拉替尼的方法
JP6691972B2 (ja) 結晶形態
WO2025108293A1 (zh) 一种双功能气管扩张剂及其结晶和制备方法
WO2019086008A1 (zh) 一种苯并三氮唑衍生物的晶型及其制备方法和用途
HK40042091B (en) Tmem16a modulators
HK40042091A (en) Tmem16a modulators
HK1147481B (zh) 多晶型
HK1212989B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptro agonist activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140521